Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease

被引：20

作者：

Raschi, Emanuel ^{[1
]}

Mazzotti, Arianna ^{[2
]}

Poluzzi, Elisabetta ^{[1
]}

De Ponti, Fabrizio ^{[1
]}

Marchesini, Giulio ^{[2
]}

机构：

[1] Univ Bologna, Dept Med & Surg Sci, Pharmacol Unit, Bologna, Italy

[2] Univ Bologna, Dept Med & Surg Sci, Unit Metab Dis & Clin Dietet, Bologna, Italy

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2018年 / 19卷 / 17期

关键词：

Nonalcoholic fatty liver disease; type; 2; diabetes; chronic liver disease; drug-induce liver injury; treatment; INTRAHEPATIC LIPID-CONTENT; COTRANSPORTER; 2; INHIBITOR; KIDNEY-DISEASE; VITAMIN-E; CARDIOVASCULAR OUTCOMES; METFORMIN USE; AMERICAN ASSOCIATION; CONTROLLED-TRIAL; STEATOHEPATITIS; PIOGLITAZONE;

D O I：

10.1080/14656566.2018.1531126

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Pharmacotherapy used to treat type 2 diabetes mellitus (T2DM) is facing a paradigm shift in clinical practice with recent cardiovascular (CV) outcome trials having a substantial impact on drug prescription with treatment having a more tailored approach. In patients with T2DM, the issue of chronic liver disease is multifaceted. However, a clinical evidence is emerging on the beneficial effect of antidiabetic medications on nonalcoholic fatty liver disease (NAFLD). Areas covered: The authors provide a synopsis on the current and upcoming pharmacotherapy for NAFLD, including the challenges with their development, focusing on drugs for T2DM. Clinical data on the potential benefits and safety issues are assessed with the aim of proposing an individualized algorithm for patient management. Both MEDLINE and ClinicalTrials.Gov are used to derive the relevant information. Expert opinion: Considering the pivotal role of insulin resistance in NAFLD, insulin sensitizers should be the treatment of choice. Accordingly, pioglitazone is the only drug with a significant effect on liver fibrosis, the driver of disease progression and long-term outcome. Among new glucose-lowering drugs, glucagon-like-peptide 1 receptor agonists or sodium-glucose cotransporter type 2 inhibitors have shown positive effects in phase II studies and are qualifying as potential candidates for NAFLD treatment in diabetes.

引用

页码：1903 / 1914

页数：12

共 97 条

[1] A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease [J].

Abul-Husn, N. S. ;

Cheng, X. ;

Li, A. H. ;

Xin, Y. ;

Schurmann, C. ;

Stevis, P. ;

Liu, Y. ;

Kozlitina, J. ;

Stender, S. ;

Wood, G. C. ;

Stepanchick, A. N. ;

Still, M. D. ;

McCarthy, S. ;

O'Dushlaine, C. ;

Packer, J. S. ;

Balasubramanian, S. ;

Gosalia, N. ;

Esopi, D. ;

Kim, S. Y. ;

Mukherjee, S. ;

Lopez, A. E. ;

Fuller, E. D. ;

Penn, J. ;

Chu, X. ;

Luo, J. Z. ;

Mirshahi, U. L. ;

Carey, D. J. ;

Still, C. D. ;

Feldman, M. D. ;

Small, A. ;

Damrauer, S. M. ;

Rader, D. J. ;

Zambrowicz, B. ;

Olson, W. ;

Murphy, A. J. ;

Borecki, I. B. ;

Shuldiner, A. R. ;

Reid, J. G. ;

Overton, J. D. ;

Yancopoulos, G. D. ;

Hobbs, H. H. ;

Cohen, J. C. ;

Gottesman, O. ;

Teslovich, T. M. ;

Baras, A. ;

Mirshahi, T. ;

Gromada, J. ;

Dewey, F. E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12) :1096-1106

[2] Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018 [J].

不详 .

DIABETES CARE, 2018, 41 :S73-S85

[3]

[Anonymous], 2010, BMJ BRIT MED J, DOI DOI 10.1136/bmj.c5702

[4]

[Anonymous], 2017, CONCEPT PAPER NEED D

[5] Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis [J].

Anstee, Quentin M. ;

Targher, Giovanni ;

Day, Christopher P. .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (06) :330-344

[6] Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program [J].

Armstrong, M. J. ;

Houlihan, D. D. ;

Rowe, I. A. ;

Clausen, W. H. O. ;

Elbrond, B. ;

Gough, S. C. L. ;

Tomlinson, J. W. ;

Newsome, P. N. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (02) :234-242

[7] Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis [J].

Armstrong, Matthew J. ;

Hull, Diana ;

Guo, Kathy ;

Barton, Darren ;

Hazlehurst, Jonathan M. ;

Gathercole, Laura L. ;

Nasiri, Maryam ;

Yu, Jinglei ;

Gough, Stephen C. ;

Newsome, Philip N. ;

Tomlinson, Jeremy W. .

JOURNAL OF HEPATOLOGY, 2016, 64 (02) :399-408

[8] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].

Armstrong, Matthew James ;

Gaunt, Piers ;

Aithal, Guruprasad P. ;

Barton, Darren ;

Hull, Diana ;

Parker, Richard ;

Hazlehurst, Jonathan M. ;

Guo, Kathy ;

Abouda, George ;

Aldersley, Mark A. ;

Stocken, Deborah ;

Gough, Stephen C. ;

Tomlinson, Jeremy W. ;

Brown, Rachel M. ;

Huebscher, Stefan G. ;

Newsome, Philip N. .

LANCET, 2016, 387 (10019) :679-690

[9] The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement [J].

Athyros, Vasilios G. ;

Alexandrides, Theodore K. ;

Bilianou, Helen ;

Cholongitas, Evangelos ;

Doumas, Michael ;

Ganotakis, Emmanuel S. ;

Goudevenos, John ;

Elisaf, Moses S. ;

Germanidis, Georgios ;

Giouleme, Olga ;

Karagiannis, Asterios ;

Karvounis, Charalambos ;

Katsiki, Niki ;

Kotsis, Vasilios ;

Kountouras, Jannis ;

Liberopoulos, Evangelos ;

Pitsavos, Christos ;

Polyzos, Stergios ;

Rallidis, Loukianos S. ;

Richter, Dimitrios ;

Tsapas, Apostolos G. ;

Tselepis, Alexandros D. ;

Tsioufis, Konstantinos ;

Tziomalos, Konstantinos ;

Tzotzas, Themistoklis ;

Vasiliadis, Themistoklis G. ;

Vlachopoulos, Charalambos ;

Mikhailidis, Dimitri P. ;

Mantzoros, Christos .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 71 :17-32

[10] The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors [J].

Avogaro, Angelo ;

Fadini, Gian Paolo .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (08) :1686-1695

← 1 2 3 4 5 6 7 8 9 10 →